Skip to main content
padlock icon - secure page this page is secure

Free Content Determination of critical concentrations of second-line anti-tuberculosis drugs with clinical and microbiological relevance

Download Article:
 Download
(PDF 452.3 kb)
 
BACKGROUND: Reliable DST against second-line anti-tuberculosis drugs (SLDs) is crucial for the management of the increasing burden of patients affected by multidrug- and extensively drug-resistant TB.

METHODS: This study utilizes 252 clinical isolates of Mycobacterium tuberculosis from five countries (Hong Kong Special Administrative Region, Korea, Latvia, Peru, Philippines) with documented treatment histories to establish clinically and microbiologically relevant critical concentrations (CCs) of six SLDs for three routine testing methods: the absolute concentration method using Löwenstein-Jensen (LJ) medium, the 1% proportion method using Middlebrook 7H10 agar medium, and the radiometric BACTEC™ 460 system.

FINDINGS: In LJ medium, CCs of capreomycin, ethionamide, kanamycin, ofloxacin, ρ-aminosalicylic acid and cycloserine (CS) were respectively 40.0, 40.0, 30.0, 3.0, 1.0 and 30.0 mg/l. In 7H10 agar medium, the respective CCs for the first five antibiotics (except CS) were 8.0, 2.0–3.0, 3.0–5.0, 1.0–1.5 and 0.5–1.0 mg/l. In BACTEC 460 broth, the respective CCs were 1.5–2.0, 1.0–1.5, 2.0–3.0, 0.5–1.0 and 0.5–1.0 mg/l. Precautions in DST interpretation was also discussed.

INTERPRETATION: By adopting this set of CCs as a global standard to define second-line drug susceptibility and resistance, as well as precautions in result interpretation, the screening, diagnosis and management of patients with drug-resistant TB can be greatly improved.
No Reference information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Keywords: critical concentration; second-line drugs; susceptibility testing; tuberculosis

Document Type: Regular Paper

Affiliations: 1: Tuberculosis Reference Laboratory, Hong Kong SAR, China 2: TB Laboratory, Massachusetts State Laboratory Institute, Boston, Massachusetts, USA 3: Partners in Health, Harvard Medical School, Boston, Massachusetts, USA 4: Stop TB Department, World Health Organization, Geneva, Switzerland 5: Stop TB Partnership, World Health Organization, Geneva, Switzerland 6: International Tuberculosis Research Center, Masan, Korea

Publication date: March 1, 2010

More about this publication?
  • The International Journal of Tuberculosis and Lung Disease publishes articles on all aspects of lung health, including public health-related issues such as training programmes, cost-benefit analysis, legislation, epidemiology, intervention studies and health systems research. The IJTLD is dedicated to the continuing education of physicians and health personnel and the dissemination of information on lung health world-wide.

    To share scientific research of immediate concern as rapidly as possible, The Union is fast-tracking the publication of certain articles from the IJTLD and publishing them on The Union website, prior to their publication in the Journal. Read fast-track articles.

    Certain IJTLD articles are also selected for translation into French, Spanish, Chinese or Russian. These are available on the Union website.

  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • International Journal of Tuberculosis and Lung Disease
  • Public Health Action
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more